A client with advanced cirrhosis of the liver is not tolerating protein well, as evidenced by abnormal laboratory values. The nurse anticipates that which of the following medications will be prescribed for the client?

1. A

   Folic acid

2. B

   Lactulose

3. C

   Thiamine

4. D

   Ethacrynic acid

Appeared in: DHS 2018 shift 1st

Explanation

• In advanced cirrhosis, the liver fails to convert ammonia, a toxic byproduct of protein metabolism, into urea for excretion.
• This leads to hyperammonemia, which causes hepatic encephalopathy, a serious neurotoxic condition.
• Lactulose is a non-absorbable disaccharide that works by acidifying the colon.
• This acidic environment traps ammonia in the gut as non-absorbable ammonium (NH₄⁺), which is then expelled from the body through feces, thereby lowering blood ammonia levels.

Why Other Options Were Wrong

• Option A: Folic acid is a B-vitamin used to treat or prevent macrocytic anemia, which is a common nutritional deficiency in patients with liver disease, but it does not lower ammonia levels.
• Option C: Thiamine (Vitamin B1) is administered to prevent or treat Wernicke-Korsakoff syndrome, a neurological complication primarily associated with chronic alcoholism, which is a common cause of cirrhosis. It does not affect ammonia metabolism.
• Option D: Ethacrynic acid is a loop diuretic used to manage fluid overload, specifically ascites and peripheral edema, which are common complications of advanced cirrhosis. It has no effect on protein metabolism or ammonia levels.

Related Visual

Clinical Relevance

• Nursing practice connection: Use the key finding related to Pharmacological management of hepatic encephalopathy in advanced cirrhosis to guide bedside assessment, documentation, and the next nursing action.
• A key nursing responsibility is to titrate the lactulose dose to achieve the therapeutic goal of 2-3 soft stools per day. This indicates effective clearance of ammonia.
• Nurses must perform frequent neurological assessments, including checking for asterixis (the 'liver flap'), to monitor the patient's response to treatment and detect worsening encephalopathy.
• What if? If the patient develops severe diarrhea, abdominal cramping, or signs of dehydration from lactulose, the nurse should hold the dose and notify the provider. The dose may need to be reduced, or an alternative medication like Rifaximin might be considered to manage the hyperammonemia.

How to Approach the Question

• First, identify the key elements in the question: the patient has 'advanced cirrhosis' and is 'not tolerating protein'.
• Connect these clinical cues. In advanced liver disease, 'protein intolerance' signifies the liver's inability to metabolize protein byproducts, leading to the buildup of toxic substances, primarily ammonia.
• Recognize that the resulting condition is hepatic encephalopathy, a neurological dysfunction.
• Evaluate the medication options based on their mechanism of action in the context of cirrhosis.
• Eliminate Folic acid and Thiamine as they are vitamins for nutritional deficiencies, not ammonia reduction.
• Eliminate Ethacrynic acid as it is a diuretic for fluid management (ascites), not for detoxification.

Concept Tested & Keywords

• Concept Tested: Pharmacological management of hepatic encephalopathy in advanced cirrhosis.
• Stem keywords: advanced cirrhosis, liver, not tolerating protein, abnormal laboratory values
• Lead-in keywords: anticipates, medications, prescribed
• Clinical cues: The combination of 'advanced cirrhosis' and 'not tolerating protein' strongly points to impaired ammonia metabolism and the development of hepatic encephalopathy.

Question ID

QNCUa-H1MQvEbTlkkdBuXn

Copy ID

Reference Book

E6 Medicine Harrison 22e Part 2 p. 621-623

E6 Pharmacology Katzung 16e p. 937-939